Overview

Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies

Status:
RECRUITING
Trial end date:
2029-04-01
Target enrollment:
Participant gender:
Summary
To find a recommended dose of PRAME-TCR-NK cells that can be given to patients with AML or MDS.
Phase:
PHASE1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Calcium Dobesilate
Cyclophosphamide
Decitabine
Dexamethasone
fludarabine
fludarabine phosphate